معرفی
Be'eri Niego is a Research Fellow at the Australian Centre for Blood Diseases, Victorian Heart Institute (VHI), Monash University. His research focuses on developing innovative therapies and imaging techniques for cardiovascular and cerebrovascular diseases, particularly stroke and cardiac fibrosis. He leads multiple research projects funded by national foundations and collaborates extensively with experts in nanomedicine, hematology, and molecular imaging.
Research Interests:
- Development of targeted thrombolytic agents for acute ischemic stroke
- Molecular imaging of cardiac fibrosis using radiotracers
- Engineering nano-carriers for brain-rejuvenating and drug delivery applications
- Preservation of blood-brain barrier integrity during thrombolysis
- Understanding plasminogen activation and clot dissolution mechanisms
- Application of nanotechnology in diabetes and cardiovascular disease
Recent Research Trends: Dr. Niego's recent publications demonstrate a strong focus on translational cardiovascular research. His work integrates nanotechnology, molecular imaging, and targeted therapeutics to address complications in stroke treatment and cardiac fibrosis. Key themes include reducing intracranial bleeding during thrombolysis, developing glucose-responsive insulin delivery systems, and creating novel imaging probes for fibrotic tissue. His research bridges hematology, neurology, and biomedical engineering.
Scientific Awards:
- Paul Korner Innovation Award
Grants and Research Leadership: Dr. Niego has secured competitive funding as a Primary Chief Investigator on multiple projects, including those from the National Heart Foundation of Australia and Monash University internal grants. His projects address critical challenges in thrombolytic therapy and cardiac imaging. He also contributes significantly to the academic community through peer review for journals such as Neuroscience, FEBS Letters, and Clinical Interventions in Aging.
Research Environment: Dr. Niego is embedded in a multidisciplinary research environment at the Australian Centre for Blood Diseases and VHI, collaborating with leading scientists like Prof. Christoph Hagemeyer, Dr. Ruhong Xu, and Dr. Karen Alt. His work is part of a larger effort to innovate in cardiovascular and cerebrovascular therapeutics using cutting-edge nanotechnology and molecular imaging approaches.
